Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years

Table 2

Indications for ADM implementation.

ADM	Product	BR with ADM ()	Oncologic indication		Aesthetic indication
			BR with no capsular	BR with capsular	Primary	Secondary augmentation after capsular
HADM	Epiflex/DIZG	15	1	3	9	2	0
PADM	Strattice/LifeCell	21	6	8	5	2	0
BADM	Tutomesh/RTI Surgical	16	2	5	3	2	4

Listing of kind of matrix used, name of product, number of breast reconstructions with certain ADMs, and indications for ADM usage (breast reconstruction (BR) with no capsular contracture, BR with capsular contracture, primary augmentation, secondary augmentation after capsular contracture). Oncologic patients made up 27% of the HADM group, 67% of the BADM group, and 44% of the BADM group; HADM: human ADM, PADM: porcine ADM, and BADM: bovine ADM; = no history of radiotherapy; = history of radiotherapy; = primary augmentation in cases with large breasts.